HHLR Advisors Ltd

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
HHLR Advisors Ltd
CRD #166112
SEC #801-77363
CIK #0001762304
AUM
Employees 203 (18% Investors, 0% Brokers)
Fees
Minimum
Phone656-603-0860
Address8 Marina Boulevard
Singapore, Singapore
Source [IAPD] [EDGAR] [Website] [LinkedIn] [Instagram]
Total AUM ($B)
806448321602010201520212027
Fees and Compensation — Form ADV Part 2A (3/31/2023) [Brochure]
Item 5, “Fees and Compensation” above for information regarding how HHLR is compensated
by its clients, the conflict of interest created by allocating investment opportunities among
clients, and how HHLR addresses such conflict of interest.

HHLR does not recommend or select third-party investment advisers for its clients. None of
HHLR, HHLR, or any other affiliate receives compensation, directly or indirectly, from any of
the others for any recommendation of the other.

However, in certain circumstances, clients could enter into joint ventures with third-party
managers or other persons with respect to the management of specified portfolio investments or
categories of portfolio investments and in connection therewith, such third-party managers or
other persons could receive management fees and/or performance-based compensation such as a
carried interest in vehicles through which such joint ventures invest. Any compensation of such
third-party managers or of joint venture partners, that will reduce a client’s returns from the
relevant portfolio investments will not offset carried interest or management fees paid to HHLR
and will increase the cost of the investors’ investment in clients.

Warehoused Investment. During the term of a client, the general partner (or similar controlling
entity) of such client or any of its affiliates could initially purchase all or part of an investment
intended to be made by such client or fund the purchase of, make a cornerstone investment in
connection with or provide financing in connection with, all or part of an investment made by
such client if, in each such case, the general partner (or similar controlling entity) of such client
determines that it would be necessary or appropriate, including from a legal, tax or regulatory
standpoint, in order to facilitate the making of such investment by such client. In such situations,
it is generally expected that, (a) the general partner (or similar controlling entity) of such client
or its affiliate (as applicable) could transfer the relevant warehoused investment to such client or
(b) such client could repay the general partner (or similar controlling entity) of such client or its
affiliate (as applicable) for such funding or financing, typically at a price or in an amount (as
applicable) generally equal to the cost of such warehoused investment plus interest thereon or on
such other terms as permitted under such client’s governing documents.. In such cases, such
client will pay all closing costs in connection with such warehoused investment, including costs
incurred in connection with the transfer of such warehoused investment to such client (if
applicable). There is no guarantee, however, that such warehoused investment will be transferred
to such client at all (due to legal, tax, regulatory or other reasons), or that the price paid by such
client for such warehoused investment would represent the price that would have been obtained
in a transaction negotiated at arm’s length.

Prior to the initial investment or initial closing of the applicable client, the general partner (or
similar controlling entity) of such client or any of its affiliates could purchase, fund the purchase
of, make a cornerstone investment in connection with or provide financing in connection with
one or more investments to temporarily warehouse such investments for such client. Following
the initial investment or closing of such client, the general partner (or similar controlling entity)
of such client will use commercially reasonable efforts to procure that the general partner (or
similar controlling entity) of such client or its affiliate (as applicable) transfers each such pre-
investment or -closing investment to such client at a price equal to the cost of such investment
plus interest thereon or on such other terms as permitted under such client's governing
documents. In connection with, or in lieu of, the foregoing, HHLR could enter into arrangements
with one or more non-affiliated persons (including any existing investors of any client and
potential investors in a client) whereby such persons agree to initially fund all or a portion of the
cost of such pre-initial investment or pre-closing investments.

There is no guarantee, however, that such pre-initial investment or pre-closing investments will
be transferred to a client at all (due to legal, tax, regulatory or other reasons), or that the price
paid by such client for each such pre-initial investment or pre-closing investment would
represent the price that would have been obtained in a transaction negotiated at arm’s length.

Other conflicts not discussed above are expected arise in connection with HHLR’s advisory
business. Investors are urged to consult the offering and other governing documents of the
relevant clients.
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2023) [Brochure]
ITEM 7: TYPES OF CLIENTS

HHLR serves as an investment adviser to pooled investment vehicles whose underlying investors
are “accredited investors” (as defined in Rule 501(a) of Regulation D under the U.S. Securities
Act of 1933, as amended) and/or “qualified purchasers” (as defined in Section 2(a)(51) of the
U.S. Investment Company Act of 1940, as amended) and/or “knowledgeable employees” (within
the meaning of Rule 3c-5 under the U.S. Investment Company Act of 1940, as amended).
Underlying investors in the pooled investment vehicles HHLR advises include endowments,
foundations, non-profit organizations, pensions, corporates, government entities, family offices,
trusts, and other businesses or institutions. As noted in Item 4, HHLR and the other Hillhouse
Investment Group entities also advise non-U.S. accounts and vehicles (including co-investment
vehicles) that are not deemed advisory clients under the Advisers Act and not discussed in this
Brochure.

HHLR also provides investment advice to institutional clients such as endowments, foundations,
non-profit organizations, pensions, corporates, government entities, family offices, trusts, and
other businesses or institutions.

Minimum Account Size

Certain of the Funds require a minimum capital commitment or investment amount, but the
general partners of such Funds may accept capital commitments or investment amounts in lesser
amounts in their sole discretion. HHLR generally does not require clients or investors to
maintain a minimum investment to continue an advisory relationship or to remain invested in the
Funds.

Advisory Agreements

HHLR’s clients typically enter into a written investment management, advisory, or similar
agreement (and/or enter into or become subject to a limited partnership or similar organizational
agreement with HHLR or one of its affiliates) in establishing an advisory relationship with
HHLR or its affiliates. HHLR will not assign any advisory agreements without client consent.
Sector Form 13F Holdings Value ($B)
Pinduoduo Inc 0.4
Alibaba Group Holding Ltd 0.3
BeiGene Ltd 0.3
FUTU Holdings Ltd 0.2
Legend Biotech Corp 0.1
Arrivent Biopharma Inc 0.1
KE Holdings Inc 0.1
Cytek Biosciences Inc 0.0
Marvell Technology Inc 0.0
I-Mab 0.0
View All
Holdings by Sector ($B)
151296302011201620212027
Type Form D Funds Date Sold AUM
HF TF-A LP 2024-03-29 623.0 M
HF ERV Investment Fund LP 2019-02-01 503.5 M
HF HHLR CF LP 2018-03-01 12.46 B
HF HHLR Fund LP 2012-03-21 27.69 B
HF YHG Investment LP 2012-03-21 1,004.1 M
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 14 41.1
(g) Pension and profit sharing plans 0 3.8
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.5
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.4
Total 20 45.9
By Discretionary
Discretionary 18 45.5
Non-Discretionary 2 0.4
Total 20 45.9
By Non-United States Persons
Non-United States Persons 45.5
United States Persons 0.4
Total 20 45.9
EDGAR Form CIK 2011 - 2026
13F-HR [0001762304]
3 [0001762304]
4 [0001762304]
SC 13D [0001762304]
SC 13G [0001762304]
Form 13D/13G Filer Form 13D/13G Subject Filed
HHLR Advisors Ltd Arrivent Biopharma Inc [2024-11-14]
HHLR Advisors Ltd Agora Inc [2022-02-14]
HHLR Advisors Ltd Cytek Biosciences Inc [2022-02-14]
HHLR Advisors Ltd on Holding AG [2022-02-14]
HHLR Advisors Ltd Smart Share Global Ltd [2021-09-27]
Hillhouse Capital Advisors Ltd Aligos Therapeutics Inc [2021-02-16]
Hillhouse Capital Advisors Ltd Leap Therapeutics Inc [2021-02-16]
Hillhouse Capital Advisors Ltd Miniso Group Holding Ltd [2021-02-16]
Hillhouse Capital Advisors Ltd Root Inc [2021-02-16]
Hillhouse Capital Advisors Ltd Beam Therapeutics Inc [2021-02-16]
Hillhouse Capital Advisors Ltd KE Holdings Inc [2021-02-16]
Hillhouse Capital Advisors Ltd FUTU Holdings Ltd [2021-02-16]
Hillhouse Capital Advisors Ltd Yatsen Holding Ltd [2020-12-16]
Hillhouse Capital Advisors Ltd I-Mab [2020-09-14]
Hillhouse Capital Advisors Ltd Viela Bio Inc [2020-02-14]
Hillhouse Capital Advisors Ltd Gossamer Bio Inc [2020-02-14]
Hillhouse Capital Advisors Ltd Bilibili Inc [2020-02-14]
Hillhouse Capital Advisors Ltd TAL Education Group [2020-02-14]
Hillhouse Capital Advisors Ltd Cellular Biomedicine Group Inc [2019-11-12]
Hillhouse Capital Advisors Ltd China Biologic Products Holdings Inc [2019-09-19]
Hillhouse Capital Advisors Ltd Kiniksa Pharmaceuticals Ltd [2019-02-14]
Hillhouse Capital Advisors Ltd MOGU Inc [2019-01-10]
Firm Profile (Form ADV)
Clients1 (90 non-US)
ServesInstitutional
Fund TypesHedge Fund
LEI549300YXBX8YW9XQIP32
Form 3/4/5 Subject 2011 - 2026
ArriVent BioPharma Inc
HHLR Advisors Ltd
Hillhouse Investment Management Ltd
BeOne Medicines Ltd
EastBridge Investment Group Corp
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
ArriVent BioPharma Inc AVBP
Common Stock
2025-12-10 Sell 555,555 $23.37 12,983,320
BeOne Medicines Ltd BGNE
Ordinary Shares
2024-12-02 Sell 17,842,500 $200.00 3,568,500,000
ArriVent BioPharma Inc AVBP
Series A Preferred Stock · derivative
2024-01-30 Conversion 55,000,000 $0.00
ArriVent BioPharma Inc AVBP
Common Stock
2024-01-30 Conversion 3,616,041
ArriVent BioPharma Inc AVBP
Common Stock
2024-01-30 Buy 555,555 $18.00 9,999,990
ArriVent BioPharma Inc AVBP
Series B Preferred Stock · derivative
2024-01-30 Conversion 4,761,903 $0.00
ArriVent BioPharma Inc AVBP
Common Stock
2024-01-30 Conversion 313,076
BeOne Medicines Ltd BGNE
Ordinary Shares
2023-06-14 Sell 273,728 $207.72 56,858,780
BeOne Medicines Ltd BGNE
Ordinary Shares
2023-06-13 Sell 611,000 $211.45 129,195,950
BeOne Medicines Ltd BGNE
Ordinary Shares
2023-06-13 Sell 313,400 $128.43 40,249,962
BeOne Medicines Ltd BGNE
Ordinary Shares
2023-06-12 Sell 968,812 $213.91 207,238,575
BeOne Medicines Ltd BGNE
Ordinary Shares
2023-06-12 Sell 281,400 $130.83 36,815,562
BeOne Medicines Ltd BGNE
Ordinary Shares
2023-06-09 Sell 328,952 $217.02 71,389,163
BeOne Medicines Ltd BGNE
Ordinary Shares
2023-06-09 Sell 213,700 $130.35 27,855,795
BeOne Medicines Ltd BGNE
Ordinary Shares
2023-06-08 Sell 1,163,825 $218.14 253,876,785
BeOne Medicines Ltd BGNE
Ordinary Shares
2022-08-22 Other 7,800 $0.00
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com